Vanutide Cridificar and the QS-21 Adjuvant in Japanese Subjects with Mild to Moderate Alzheimer’ s Disease: Results from Two Phase 2 Studies

Publisher： Bentham Science Publishers

E-ISSN： 1875-5828|12|3|242-254

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.12, Iss.3, 2015-03, pp. : 242-254

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study

Current Alzheimer Research, Vol. 15, Iss. 13, 2018-12 ,pp. : 1231-1243

Bentham Science Publishers

Access to resources Recommend Favorite

Awareness of cognitive deficits and clinical competence in mild to moderate Alzheimer’s disease: their relevance in clinical practice

By Gambina G. Bonazzi A. Valbusa V. Condoleo M. Bortolami O. Broggio E. Sala F. Moretto G. Moro V.

Neurological Sciences, Vol. 35, Iss. 3, 2014-03 ,pp. : 385-390

Springer Publishing Company

Access to resources Recommend Favorite

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

By Ott Brian Blake Lesley Kagan Ethel Resnick Malca

Journal of Neurology, Vol. 254, Iss. 3, 2007-03 ,pp. : 351-358

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of Frailty in Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-analysis

Current Alzheimer Research, Vol. 14, Iss. 12, 2017-10 ,pp. : 1256-1263

Bentham Science Publishers

Access to resources Recommend Favorite

Platelet phospholipase A₂ activity in Alzheimer’s disease and mild cognitive impairment

By Gattaz W. F. Forlenza O. V. Talib L. L. Barbosa N. R. Bottino C. M. C.

Journal of Neural Transmission, Vol. 111, Iss. 5, 2004-05 ,pp. : 591-601

Springer Publishing Company

Access to resources Recommend Favorite